JP2022543244A5 - - Google Patents

Info

Publication number
JP2022543244A5
JP2022543244A5 JP2022506659A JP2022506659A JP2022543244A5 JP 2022543244 A5 JP2022543244 A5 JP 2022543244A5 JP 2022506659 A JP2022506659 A JP 2022506659A JP 2022506659 A JP2022506659 A JP 2022506659A JP 2022543244 A5 JP2022543244 A5 JP 2022543244A5
Authority
JP
Japan
Prior art keywords
compound
approximately
optionally substituted
aminosterol
symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543244A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044392 external-priority patent/WO2021025974A1/en
Publication of JP2022543244A publication Critical patent/JP2022543244A/ja
Publication of JP2022543244A5 publication Critical patent/JP2022543244A5/ja
Pending legal-status Critical Current

Links

JP2022506659A 2019-08-02 2020-07-31 ヒトスクアラミン誘導体、それを含む関連組成物、およびそれを用いた方法 Pending JP2022543244A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962882318P 2019-08-02 2019-08-02
US62/882,318 2019-08-02
US202063036828P 2020-06-09 2020-06-09
US63/036,828 2020-06-09
PCT/US2020/044392 WO2021025974A1 (en) 2019-08-02 2020-07-31 Human squalamine derivatives, related compositions comprising the same, and methods of using the same

Publications (2)

Publication Number Publication Date
JP2022543244A JP2022543244A (ja) 2022-10-11
JP2022543244A5 true JP2022543244A5 (cg-RX-API-DMAC7.html) 2023-08-07

Family

ID=74503104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506659A Pending JP2022543244A (ja) 2019-08-02 2020-07-31 ヒトスクアラミン誘導体、それを含む関連組成物、およびそれを用いた方法

Country Status (5)

Country Link
US (1) US20220372066A1 (cg-RX-API-DMAC7.html)
EP (1) EP4007765A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022543244A (cg-RX-API-DMAC7.html)
CA (1) CA3149480A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021025974A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001449A (es) 2019-08-02 2022-04-06 Enterin Inc Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
WO2021216399A1 (en) * 2020-04-20 2021-10-28 Enterin, Inc. Pulmonary aminosterol compositions and methods of using the same to treat microbial infections
WO2022226116A1 (en) * 2021-04-21 2022-10-27 Oxeia Biopharmaceuticals, Inc. Ghrelin treatment of brain dysfunction due to viral infection
WO2023038858A1 (en) * 2021-09-10 2023-03-16 Edifice Health, Inc. Methods and compositions for diagnosing and treating covid-19
CN113975278B (zh) * 2021-10-29 2023-04-07 中国科学院昆明动物研究所 溴隐亭在制备治疗非洲猪瘟的产品中的应用
WO2023146842A1 (en) * 2022-01-25 2023-08-03 Enterin, Inc. C25 r and s isomers of aminosterols and methods of making and using the same
WO2023146838A1 (en) * 2022-01-25 2023-08-03 Enterin, Inc. Methods for treating or preventing neurodegenerative disease using a combination of aminosterols and an insulin compound
CN118085053A (zh) * 2022-11-25 2024-05-28 深圳先进技术研究院 以Inx5基因或以Inx5蛋白作为作用靶点的物质的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157594A1 (en) * 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
AU723663C (en) * 1995-06-07 2001-11-01 Magainin Pharmaceuticals, Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
CA2985271A1 (en) * 2007-09-06 2009-03-12 Ohr Pharmaceutical, Inc. A method for treating diabetes
KR20150003798A (ko) * 2012-04-20 2015-01-09 오에이치알 파마서티컬, 인코포레이티드 Ptp1b 연관 질병의 치료용 아미노스테로이드
EP2934543B1 (en) * 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
GB201316050D0 (en) * 2013-09-10 2013-10-23 Univ Swansea Deuterated compounds
GB201303589D0 (en) * 2013-02-27 2013-04-10 Univ Swansea Compound and method for the treatment of neurodegenerative conditions
CN105980396B (zh) * 2013-12-20 2019-03-22 普瑞维卡斯有限公司 对映异构-孕酮及其中间体的合成
FR3055802B1 (fr) * 2016-09-15 2018-08-24 Virbac Derives amides de squalamine pour le traitement des infections
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
MX2022001449A (es) * 2019-08-02 2022-04-06 Enterin Inc Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment

Similar Documents

Publication Publication Date Title
JP2022543242A5 (cg-RX-API-DMAC7.html)
JP5932883B2 (ja) 障害を処置するための方法および組成物
RU2302420C9 (ru) Ингибиторы ксантин-фосфодиэстеразы v, способ их получения, фармацевтическая композиция, применение и способ лечения
CN1065531C (zh) 用作一氧化氮合成酶抑制剂的氨基四唑衍生物
JPWO1998047505A1 (ja) 神経ペプチドy受容体拮抗剤
EP3157926B1 (en) Organic compounds
JP2015007096A (ja) 運動障害の予防および/または治療剤
CA2517893C (fr) Application a titre de medicaments de derives de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
JP2020023496A6 (ja) 有機化合物
JP2009504748A (ja) R(+)プラミペキソールを用いた神経回復
AU2015239112A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
JP2002527474A (ja) 躁病および双極性障害の治療法
BE834794A (fr) Acide 3-trihydroxygermano-propionique
JP2002544232A (ja) N−デスメチルゾピクロンの製造方法および使用方法
WO2016149248A1 (en) N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto
EP4180428A1 (en) Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
EP4097119B1 (en) Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases
JP6173352B2 (ja) 筋萎縮性側索硬化症の治療方法
FR2894968A1 (fr) Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
JP3509637B2 (ja) 睡眠障害予防治療剤
JPH07509478A (ja) ホスホリル−l−セリン−n−アシル−スフィンゴシンの治療用使用
WO2012097750A1 (zh) 用于治疗阳痿的吡唑并嘧啶酮化合物和咪唑并三嗪酮化合物
JP5960695B2 (ja) パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用
JPWO2006006617A1 (ja) 中枢神経疾患発症後の機能障害の回復促進剤
JPH0233689B2 (cg-RX-API-DMAC7.html)